A mouse model of overexpression of human IL-6 by tissue-resident macrophages in the context of LPS-induced inflammation
https://doi.org/10.15789/1563-0625-AMM-16918
Abstract
Chronic inflammation caused by overexpression of IL-6 underlies a number of pathological conditions Mouse models of systemic chronic inflammation with overexpression of human IL-6 (hIL-6) are in demand not only in the context of studying the molecular mechanisms of inflammation, but also in assessing the effectiveness of clinically approved or newly developed IL-6 inhibitors. One experimental approach in addressing such models in mice relies on the induction of systemic acute inflammation in response to lipopolysaccharide (LPS) administration. This work describes mice with tamoxifen-dependent overexpression of human IL-6 in CX3CR1+ myeloid cells in the context of systemic inflammation induced by LPS administration. Our study demonstrates that the highest expression of the transgene carrying IL6 was observed in the heart, while high production of this cytokine was detected in the blood serum. In response to LPS administration, the production of hIL-6 in the blood increased in transgenic mice, while the production of mIL-6 also increased and was comparable to that in wild-type mice. The consequences of high systemic production of hIL-6, which in our model originates from CX3CR1+ tissue-resident macrophages, were noticeable even in the organs in which these cells are not present. Thus, significant amounts of hIL-6 were detected in tissue lysates of the lungs of transgenic mice after LPS administration. Evaluation of the expression of genes encoding cytokines and markers of tissue remodeling upon injury using quantitative real-time PCR showed significant changes in their expression in the context of LPS-induced systemic inflammation. Thus, this work demonstrates the feasibility of using a mouse model with tamoxifen-dependent transgene activation in CX3CR1+ tissue-resident macrophages to study the effects of systemic overexpression of IL-6 and pharmacological blockade of this cytokine with clinically approved or newly developed inhibitors in the context of experimentally induced diseases.
About the Authors
N. R. ChicherinaRussian Federation
Nelya R. Chicherina - Мaster’s Degree Student, Sirius University of Science and Technology; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences.
Krasnodar Region
Phone: +7 (968) 034-43-97
Fax: +7 (499) 135-14-05
Competing Interests:
None
E. A. Gorshkova
Russian Federation
PhD (Biology), Senior Research Associate, Laboratory of Molecular Mechanisms of Immunity, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences.
Moscow
Competing Interests:
None
E. A. Myachev
Russian Federation
Research Associate, Laboratory of Molecular Mechanisms of Immunity, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences; Lomonosov Moscow State University, Faculty of Biology.
Moscow
Competing Interests:
None
A. S. Yakovleva
Russian Federation
Research Associate, Laboratory of Molecular Mechanisms of Immunity, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences; Lomonosov Moscow State University, Faculty of Biology.
Moscow
Competing Interests:
None
A. M. Litvinova
Russian Federation
Master’s Degree Student, Sirius University of Science and Technology
Krasnodar Region
Competing Interests:
None
O. A. Namakanova
Russian Federation
Junior Research Associate, Laboratory of Molecular Mechanisms of Immunity, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences.
Moscow
Competing Interests:
None
R. V. Zvartsev
Russian Federation
Junior Research Associate, Laboratory of Molecular Mechanisms of Immunity, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences.
Moscow
Competing Interests:
None
S. A. Nedospasov
Russian Federation
PhD, MD (Biology), Professor, Full Member, Russian Academy of Sciences, Head, Laboratory of Molecular Mechanisms of Immunity, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences; Head, Division of Immunobiology and Biomedicine, Sirius University of Science and Technology.
Moscow; Krasnodar Region
Competing Interests:
None
M. S. Drutskaya
Russian Federation
PhD, MD (Biology), Leading Research Associate, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences; Associate Professor, Sirius University of Science and Technology.
Moscow; Krasnodar Region
Competing Interests:
None
References
1. Gorshkova E.A., Zvartsev R.V., Drutskaya M.S., Gubernatorova E.O. Humanized mouse models of proinflammatory cytokine genes overexpression. Molekulyarnaya biologiya = Molecular Biology, 2019, Vol. 53, no. 5, pp. 755-773. (In Russ.)
2. Zvartsev R.V., Korshunova D.S., Gorshkova E.A., Nosenko M.A., Korneev K.V., Maksimenko O.G., Korobko I.V., Kuprash D.V., Drutskaya M.S., Nedospasov S.A., Deikin A.V. Neonatal Lethality and Inflammatory Phenotype of the New Transgenic Mice with Overexpression of Human Interleukin-6 in Myeloid Cells. Doklady Akademii nauk = Reports of the Academy of Sciences, 2018, Vol. 483, no. 1, pp. 344-347. (In Russ.)
3. Leshchenko I.V., Zherebtsov A.D. Idiopathic pulmonary fibrosis: modern view of pathogenesis and the role of biomarkers. RMZh = Russian Medical Journal, 2018, Vol. 10, no. I, pp. 6-10. (In Russ.)
4. Gubernatorova E.O., Gorshkova E.A., Namakanova O.A., Zvartsev R.V., Hidalgo J., Drutskaya M.S., Tumanov A.V., Nedospasov S.A. Non-redundant Functions of IL-6 Produced by Macrophages and Dendritic Cells in Allergic Airway Inflammation. Front. Immunol., 2018, Vol. 9, 2718. doi: 10.3389/fimmu.2018.02718.
5. Gubernatorova E.O., Gorshkova E.A., Polinova A.I., Drutskaya M.S. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev., 2020, Vol. 53, pp. 13-24.
6. Opdenakker G., van den Steen P.E., Dubois B., Nelissen I., van Coillie E., Masure S., Proost P., van Damme J. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol., 2001, Vol. 69, no. 6, pp. 851-859.
7. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc., 2008, Vol. 3, no. 6, pp. 1101-1108.
8. Sharma A., Wang J., Gandhi C.R. CD14 is not required for carbon tetrachloride-induced hepatic inflammation and fibrosis with or without lipopolysaccharide challenge. J. Cell Physiol., 2023, Vol. 238, no. 7, pp. 1530-1541.
9. Tanaka T., Narazaki M., Masuda K., Kishimoto T. Regulation of IL-6 in Immunity and Diseases. Adv. Exp. Med. Biol., 2016, Vol. 941, pp. 79-88.
10. Yona S., Kim K.W., Wolf Y., Mildner A., Varol D., Breker M., Strauss-Ayali D., Viukov S., Guilliams M., Misharin A., Hume D.A., Perlman H., Malissen B., Zelzer E., Jung S. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity, 2013, Vol. 38, no. 1, pp. 79-91.
Review
For citations:
Chicherina N.R., Gorshkova E.A., Myachev E.A., Yakovleva A.S., Litvinova A.M., Namakanova O.A., Zvartsev R.V., Nedospasov S.A., Drutskaya M.S. A mouse model of overexpression of human IL-6 by tissue-resident macrophages in the context of LPS-induced inflammation. Medical Immunology (Russia). 2024;26(5):919-926. (In Russ.) https://doi.org/10.15789/1563-0625-AMM-16918